Pascoe S, Edelman S, Kidman A
Health Psychology Unit, The University of Technology, Sydney, New South Wales, Australia.
Aust N Z J Psychiatry. 2000 Oct;34(5):785-91. doi: 10.1080/j.1440-1614.2000.00817.x.
The study aimed to estimate the prevalence of anxiety and depression within a cross section of cancer patients in the Sydney region, and to assess the use of and degree of satisfaction with available support services.
A survey was conducted at oncology outpatient departments of four Sydney hospitals. Participants completed the Hospital Anxiety and Depression Scale (HADS) and a questionnaire seeking information on their use of patient support services, as well as demographic and clinical information.
A total of 504 valid questionnaires were returned. Using a cut-off score of 11 on the HADS, the prevalence of clinically significant anxiety and depression was 11.5% and 7.1% respectively; 17% of patients had received individual counselling while 6.5% had attended support groups. The majority of patients who had attended counselling or support groups reported them to have been 'extremely' or 'reasonably' helpful (86% and 83% respectively). Of the patients who were experiencing clinically significant anxiety or depression, 75% had not received any counselling or psychological treatment. The main factors which predicted clinically significant anxiety or depression were: restricted activity levels, advanced disease, a non-English-speaking background and being female.
While the prevalence of clinically significant anxiety or depression detected by the HADS was reasonably low, a substantial number of possible cases were identified. The majority of affected patients were not accessing counselling or psychological treatment. Systematic screening of oncology patients at hospital entry might enable more immediate identification of clinically affected patients, who could then be referred for further testing or psychological treatment.
本研究旨在估计悉尼地区癌症患者横断面中焦虑和抑郁的患病率,并评估现有支持服务的使用情况和满意度。
在悉尼四家医院的肿瘤门诊进行了一项调查。参与者完成了医院焦虑抑郁量表(HADS)以及一份关于其使用患者支持服务的问卷,以及人口统计学和临床信息。
共返回504份有效问卷。使用HADS的临界值11,临床上显著焦虑和抑郁的患病率分别为11.5%和7.1%;17%的患者接受了个体咨询,6.5%的患者参加了支持小组。大多数参加咨询或支持小组的患者报告这些服务“非常”或“相当”有帮助(分别为86%和83%)。在经历临床上显著焦虑或抑郁的患者中,75%未接受任何咨询或心理治疗。预测临床上显著焦虑或抑郁的主要因素是:活动水平受限、疾病晚期、非英语背景和女性。
虽然HADS检测出的临床上显著焦虑或抑郁的患病率相当低,但仍发现了大量可能的病例。大多数受影响的患者未接受咨询或心理治疗。在医院入院时对肿瘤患者进行系统筛查可能有助于更及时地识别临床上受影响的患者,然后可将其转诊进行进一步检查或心理治疗。